Gut microbiome alterations in patients with stage 4 hepatitis COriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
Researchers compared gut microbiome composition between Egyptian patients with stage 4 (cirrhotic) hepatitis C virus infection and healthy individuals. Egypt has the world's highest HCV prevalence, motivating the investigation.
How was it studied?
Stool samples from six stage 4 HCV patients and eight healthy adult male controls were profiled by high-throughput 16S rRNA gene sequencing (V4 region, Illumina MiSeq). Taxonomic composition and diversity were analyzed using QIIME and LEfSe, and results were cross-checked against American Gut reference samples.
What did they find?
Healthy individuals had higher gut microbial alpha-diversity than HCV patients. Bacteroidetes, driven largely by Prevotella, plus Faecalibacterium, were more abundant in HCV patients, while Firmicutes, Proteobacteria, and Actinobacteria were more abundant in healthy controls, along with Ruminococcus and Clostridium. Bifidobacterium was detected only in healthy individuals, not in any HCV patient.
Why it matters
The findings suggest chronic HCV infection and liver dysfunction may reshape the gut microbiome, potentially through bacterial translocation or impaired liver-driven digestion. The authors propose Prevotella and Faecalibacterium versus Bifidobacterium as candidate biomarkers for future study.